

BRIEF COMMUNICATION OPEN



Improving clinical management of macular neovascularisation secondary to angioid streaks

Godhuli Patri¹, Ibtisam Elaroud¹, Nicholas Beare^{1,2} and Savita Madhusudhan^{1,2}✉

© The Author(s) 2023

Eye; <https://doi.org/10.1038/s41433-023-02797-1>

Angioid streaks (AS) occur due to breaks in a degenerated and weakened Bruch's membrane and typically radiate outwards from the optic disc. They could be idiopathic, or associated with systemic diseases such as pseudoxanthoma elasticum (PXE), Ehler–Danlos syndrome, Paget's disease, Sickle cell disease, and other hemoglobinopathies [1]. Macular neovascularisation (MNV) is a common cause of central visual loss and occurs in 42–86% of cases, with bilateral involvement in up to 71% [2].

We would like to share with the readers a protocol defining management of AS-related MNV following a review of our clinical practice for patients referred between 2014 and 2022 to St. Paul's Eye Department, Royal Liverpool University Hospital, for either active management or second opinion. We identified patients with secondary MNV for analysis. Data pertaining to patient demographics, management of MNV, and visual outcomes was retrospectively collected from electronic patient records.

Of the 24 patients with AS, 18 (10 males; 31 eyes) had MNV. The average age of these patients was 57.9 years, 55.6% had a diagnosis of PXE; 72.2% had bilateral MNV. Mean follow-up was 48 months (4 months–13 years). The location of MNV was subfoveal, juxtafoveal, and extrafoveal in 32%, 32%, and 36% of eyes, respectively. Details of anti-VEGF intravitreal therapy were available in 21 out of 31 (67.7%) eyes. Twelve eyes had aflibercept, 9 received ranibizumab initially followed by aflibercept. The mean number of injections per eye was 20.6, reducing

to 16.7 (range 2–45) when excluding one patient who had 89 injections. The mean best-recorded logMAR visual acuity at baseline and final follow-up was 0.57 and 0.50, respectively. Overall, 52% of eyes gained, 29% lost and 19% maintained baseline visual acuity at the final follow-up. One incidence of endophthalmitis with recovery to baseline visual acuity was noted. At final follow-up, central retinal thickness on macular OCT was lower in 12 eyes (57.2%), remained stable in 8 eyes (38%), and was worse in 1 eye (4.8%) compared to baseline.

Although our visual outcomes are comparable to published studies [3] with different anti-VEGF agents using *p.r.n.* regimes, our patients had received a higher average number of injections per eye (Table 1). Given the lack of established guidelines to inform treatment decisions for AS-related MNV, we devised a departmental protocol to aid clinical decision-making that may be more widely applicable (Fig. 1).

Although anti-VEGF therapy can stabilise or even improve visual outcomes in AS-related MNV, MNV can be tenacious with a high recurrence rate, often requiring long-term anti-VEGF therapy, as seen in our case series. Our results are affected by the retrospective nature of the review and a high degree of subjectivity in re-treatment decisions by clinicians. We have defined precise re-treatment criteria as part of the management, which we believe will prevent under or over-treatment and aim to re-audit our results in future. Given the limitations of our small sample size, further prospective studies with larger sample

¹St. Paul's Eye Unit, Royal Liverpool University Hospital, Prescot Street, Liverpool L7 8XP, UK. ²Department of Eye and Vision Sciences, University of Liverpool, William Henry Duncan Building, 6 West Derby Street, Liverpool L7 8TX, UK. ✉email: savita.madhusudhan@liverpoolft.nhs.uk

Received: 25 September 2023 Revised: 30 September 2023 Accepted: 11 October 2023

Published online: 28 November 2023

Table 1. Comparison of different studies on management of MNV in AS.

Study	Anti-VEGF	Regime	No. of eyes	Age (years), mean	Follow-up (months), mean	No. of injections, mean	Visual acuity			Assessment	Outcome measures	CRT reduction, mean
							Improved	Stable	Reduced			
Sawa et al. [4]	Bevacizumab	PRN	15	59	19	4.5	5 (33%)	8 (54%)	2 (13%)	BCVA, OCT, FA	BCVA, FA	NA
Elmatri et al. [5]	Bevacizumab	PRN	18	NA	12	4.8	11 (61.1%)	7 (38.8%)	0 (0%)	BCVA, OCT, FA	BCVA, CRT	103 u
Teixeira et al. [6]	Bevacizumab	PRN	5	36	25	5.8	5 (100%)	0 (0%)	0 (0%)	BCVA, OCT, FA, ICG	BCVA, CRT, FA	69 u
Finger et al. [7]	Bevacizumab	PRN	16	55	28	6.5	13 (81%)	0 (0%)	3 (19%)	BCVA, OCT, FA, ICG	BCVA, CRT, FA	39.8 u
Wiegand et al. [8]	Bevacizumab	PRN	9	70.8	19	4.4	4 (44.4%)	4 (44.4%)	1 (11.1%)	BCVA, OCT, FA	BCVA, CRT	67.7 u
Bhatnagar et al. [9]	Bevacizumab	PRN	9	53.5	6	1.8	2 (22%)	7 (78%)	0 (0%)	BCVA, OCT, FA	BCVA, CRT	161 u
Ladas et al. [10]	Ranibizumab	PRN	15	58.9	12	7.1	8 (53.3%)	6 (40%)	1 (6.7%)	BCVA, OCT, FA	BCVA, CRT, FA	107.1 u
Mimoun et al. [2]	Ranibizumab	PRN	35	63.7	24.1	5.7	4 (11.4%)	26 (74.3%)	5 (14.3%)	BCVA, OCT, FA	BCVA, CRT	NA
Vadala et al. [11]	Ranibizumab	PRN	9	58	14	5	7 (78%)	1 (11%)	1 (11%)	BCVA, OCT	BCVA, CRT	46 u
Shah and Amaoku [12]	Ranibizumab	PRN	12	NA	21.75	5.75	3 (25%)	8 (66.67%)	1 (8.33%)	BCVA, OCT	BCVA, CRT	38.8 u
Tilleul et al. [13]	Ranibizumab	PRN	35	63.2	48.6	9.9	5 (14.3%)	17 (48.6%)	13 (37.1%)	BCVA, OCT, FA	BCVA, CRT, FA	NA
Grenet et al. [14]	Ranibizumab	PRN	98	55.5	36.5	4.1	3 (15.8%)	10 (52.6%)	6 (31.6%)	BCVA, OCT or FA	BCVA, CRT, FA	46 u
Gilem et al. [15]	Aflibercept	PRN	15	53	12	6.7	4 (26.7%)	10 (66.7%)	1 (6.6%)	BCVA, OCT, FA, retinal sensitivity	BCVA, CRT, FA, retinal sensitivity	38 u
Our study	Ranibizumab + Aflibercept	PRN	21	57.9	48	16.7	11 (52.3%)	4 (19%)	6 (28.5%)	BCVA, OCT, FA	BCVA, CRT	67.9 u

BCVA best-corrected visual acuity, CRT central retinal thickness, OCT ocular coherence tomography, FA fluorescein angiography, ICG indocyanine green.




Fig. 1 St. Paul's Eye Department AS-related MNV management protocol. EDI enhanced depth imaging, OCT-A ocular coherence tomography angiography, SHRM subretinal hyperreflective material, VEGF vascular endothelial growth factor, HbA1C haemoglobin A1c.

sizes and longer follow-up duration are required to support our conclusions.

REFERENCES

1. Nadelmann JB, et al. Systemic disease associations with angioid streaks in a large healthcare claims database. *Eye*. 2022;37:1–6. <https://doi.org/10.1038/s41433-022-02189-x>
2. Mimoun G, et al. Intravitreal ranibizumab for choroidal neovascularization in angioid streaks. *American journal of ophthalmology*. 2010;150:692–700.e1. <https://doi.org/10.1016/j.ajo.2010.06.004>
3. Gliem M, et al. Treatment of choroidal neovascularization due to angioid streaks: a comprehensive review. *Retina (Philadelphia, Pa.)*. 2013;33:1300–14. <https://doi.org/10.1097/IAE.0b013e3182914d2b>
4. Sawa M, et al. Long-term Results of Intravitreal Bevacizumab Injection for Choroidal Neovascularization Secondary to Angioid Streaks. *American Journal of Ophthalmology*. 2009;148(4):584–590. <https://doi.org/10.1016/j.ajo.2009.04.026>

5. El Matri L, et al. Intravitreal bevacizumab for the treatment of choroidal neovascularization secondary to angioid streaks: one year of follow-up. *Acta Ophthalmologica*. 2011;89:641–646. <https://doi.org/10.1111/j.1755-3768.2009.01836.x>
6. Teixeira A, et al. Choroidal neovascularization treated with intravitreal injection of bevacizumab (Avastin) in angioid streaks. *Acta Ophthalmologica*. 2006;84:835–836. <https://doi.org/10.1111/j.1600-0420.2006.00762.x>
7. Finger RP et al. Monthly ranibizumab for choroidal neovascularizations secondary to angioid streaks in pseudoxanthoma elasticum: a one-year prospective study. *American Journal of Ophthalmology*, 152:695–703. <https://doi.org/10.1016/j.ajo.2011.03.022>
8. Wiegand TW, et al. Intravitreal bevacizumab (Avastin) treatment of choroidal neovascularisation in patients with angioid streaks. *Br J Ophthalmol*. 2009;93(Jan):47–51. <https://doi.org/10.1136/bjo.2008.143461>
9. Bhatnagar P, et al. Intravitreal bevacizumab for the management of choroidal neovascularization in pseudoxanthoma elasticum. *Retina*. 2007;27(Sep):897–902. <https://doi.org/10.1097/IAE.0b013e31809ff5df>
10. Ladas ID, et al. Intravitreal ranibizumab treatment of macular choroidal neovascularization secondary to angioid streaks one-year results of a prospective study. *Retina*. 2010;30:1185–1189. <https://doi.org/10.1097/IAE.0b013e3181d2f11d>. September 2010
11. Vadalà M, et al. Angioid streak-related choroidal neovascularization treated by intravitreal ranibizumab. *Retina*. 2010;30(Jun):903–7. <https://doi.org/10.1097/IAE.0b013e3181cafc75>
12. Shah M, et al. Intravitreal ranibizumab for the treatment of choroidal neovascularisation secondary to angioid streaks. *Eye (Lond)*. 2012;26(Sep):1194–8. <https://doi.org/10.1038/eye.2012.116>
13. Tilleul J, et al. Intravitreal ranibizumab for choroidal neovascularization in angioid streaks. Four-Year Follow-up. *Retina*. 2016;36(Mar):483–91. <https://doi.org/10.1097/IAE.0000000000000745>
14. Mimoun G, et al. Ranibizumab for choroidal neovascularization secondary to pseudoxanthoma elasticum: 4-year results from the PIXEL study in France. *Graefes Arch Clin Exp Ophthalmol*. 2017;255(Aug):1651–1660. <https://doi.org/10.1007/s00417-017-3685-y>
15. Gliem M, et al. Aflibercept for choroidal neovascularizations secondary to pseudoxanthoma elasticum: a prospective study. *Graefes Arch Clin Exp Ophthalmol*. 2020;258(Feb):311–318. <https://doi.org/10.1007/s00417-019-04551-4>

AUTHOR CONTRIBUTIONS

GP: data collection and analysis, manuscript writing. IE: data collection and analysis. NB: review of data analysis. SM: study concept and design, review of data and manuscript.

COMPETING INTERESTS

The authors declare no competing interests.

ADDITIONAL INFORMATION

Correspondence and requests for materials should be addressed to Savita Madhusudhan.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023